Tumor-derived Exosomes and Tumor HallmarksWe develop technologies for the detection of tumor-derived material to enable early cancer screening and the next generation of cancer diagnostics.
IMAGINE A WORLD IN WHICH CANCER DIAGNOSIS IS POSSIBLE FROM A
SIMPLE BLOOD DRAW
Cancer is a heterogeneous and complex disease characterized by abnormal cell growth. Some fundamental processes arise as common hallmarks of all cancers and can provide unifying elements for disease detection. Exosomics has dedicated extensive efforts to identify the so called “Warburgian” unifying markers so they can be exploited in liquid biopsy.
The revolutionary solution came from the detection of this category of markers on circulating exosomes, enabling selective isolation of tumor–derived vesicles and their contents.
Exosomes are membranous nanovesicles released from all living cells in a finely regulated way and reflecting the cell–of–origin function and status. These tiny lipidic vesicles are true surrogates of a parent cell: they carry specific payload of molecules (proteins, lipids, nucleic acids etc.). Selective isolation and analysis of circulating tumor originated exosomes enables a true non-invasive tumor tissue biopsy.
CANCER SCREENING: BEST PROTECTION IS EARLY DETECTION
Most cancers could be cured if detected at an early enough stage
Current cancer diagnostics is invariably invasive, not-conclusive and multi-step process, with associated high costs and considerable patients discomfort. Screening tests are today available for only a few solid tumors and most of the tumors are not detected at an early stage due to the lack of appropriate tools and biomarkers.
Exosomics provides revolutionary solution for solid tumor screening
– One test fits all tumors
– Non-invasive – blood based
– Low interval, low cost
– High accuracy
PRECISION MEDICINE STARTS WITH PRECISION DIAGNOSTICS
BETTER UNDERSTANDING – BETTER TREATMENT
We use a spectrum of affinity isolation tools that can provide ever more selective enrichment of clinically relevant targets from the sample enabling true tumor biopsy from blood.
This is the basis of our seleCTEV and soRTEV assay families for analysis of DNA alterations (point mutations, insertions, deletions) and RNA isoforms (splicing variants, gene fusions, gene amplifications) implicated in prognosis and selection of the right treatment for oncological patients.